» Articles » PMID: 27008897

Age-targeted HIV Treatment and Primary Prevention As a 'ring Fence' to Efficiently Interrupt the Age Patterns of Transmission in Generalized Epidemic Settings in South Africa

Overview
Journal Int Health
Specialty Health Services
Date 2016 Mar 25
PMID 27008897
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Generalized HIV epidemics propagate to future generations according to the age patterns of transmission. We hypothesized that future generations could be protected from infection using age-targeted prevention, analogous to the ring-fencing strategies used to control the spread of smallpox.

Methods: We modeled age-targeted or cohort-targeted outreach with HIV treatment and/or prevention using EMOD-HIV v0·8, an individual-based network model of HIV transmission in South Africa.

Results: Targeting ages 20 to 30 with intensified outreach, linkage, and eligibility for antiretroviral therapy (ART) averted 45% as many infections as universal outreach for approximately one-fifth the cost beyond existing HIV services. Though cost-effective, targeting failed to eliminate all infections to those under 20 due to vertical and inter-generational transmission. Cost-effectiveness of optimal prevention strategies included US$6238 per infection averted targeting ages 10-30, US$5031 targeting 20-30, US$4279 targeting 22-27, and US$3967 targeting 25-27, compared to US$10 812 for full-population test-and-treat. Minimizing burden (disability-adjusted life years [DALYs]) rather than infections resulted in older target age ranges because older adults were more likely to receive a direct health benefit from treatment.

Conclusions: Age-targeted treatment for HIV prevention is unlikely to eliminate HIV epidemics, but is an efficient strategy for reducing new infections in generalized epidemics settings.

Citing Articles

Mitigating HIV risk associated with widow cleansing and wife inheritance using combined biomedical and structural interventions in western Kenya: a mathematical modeling study.

Gathungu D, Ojiambo V, Kimathi M, Kaftan D, Kim H, Citron D BMC Med. 2025; 23(1):88.

PMID: 39940027 PMC: 11823008. DOI: 10.1186/s12916-025-03906-5.


Estimated contributions and future mitigation strategies for HIV risk around funeral practices in western Kenya: a mathematical modeling study.

Mwalili S, Gathungu D, Chemutai J, Musyoka E, Bridenbecker D, Kirkman 4th C BMC Med. 2025; 23(1):85.

PMID: 39939974 PMC: 11823116. DOI: 10.1186/s12916-025-03907-4.


Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis.

Milali M, Resar D, Kaftan D, Campbell J, Olowu A, Edwards D Front Reprod Health. 2023; 5:1144217.

PMID: 37266447 PMC: 10230827. DOI: 10.3389/frph.2023.1144217.


Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models.

Bansi-Matharu L, Mudimu E, Martin-Hughes R, Hamilton M, Johnson L, Ten Brink D Lancet Glob Health. 2022; 11(2):e244-e255.

PMID: 36563699 PMC: 10005968. DOI: 10.1016/S2214-109X(22)00515-0.


Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018.

Haeuser E, Serfes A, Cork M, Yang M, Abbastabar H, Abhilash E BMC Med. 2022; 20(1):488.

PMID: 36529768 PMC: 9760541. DOI: 10.1186/s12916-022-02639-z.


References
1.
Jemmott L, Jemmott 3rd J, Ngwane Z, Icard L, OLeary A, Gueits L . 'Let Us Protect Our Future' a culturally congruent evidenced-based HIV/STD risk-reduction intervention for young South African adolescents. Health Educ Res. 2013; 29(1):166-81. PMC: 3894663. DOI: 10.1093/her/cyt072. View

2.
Rosen S, Fox M . Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011; 8(7):e1001056. PMC: 3139665. DOI: 10.1371/journal.pmed.1001056. View

3.
Fraser S . Leicester and smallpox: the Leicester method. Med Hist. 1980; 24(3):315-32. PMC: 1082657. DOI: 10.1017/s0025727300040345. View

4.
Donnell D, Baeten J, Kiarie J, Thomas K, Stevens W, Cohen C . Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375(9731):2092-8. PMC: 2922041. DOI: 10.1016/S0140-6736(10)60705-2. View

5.
Eaton J, Menzies N, Stover J, Cambiano V, Chindelevitch L, Cori A . Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014; 2(1):e23-34. DOI: 10.1016/S2214-109X(13)70172-4. View